Press Release

Illumina to Announce First Quarter 2012 Results on Monday, April 23, 2012

SAN DIEGO, Apr 16, 2012 (BUSINESS WIRE) --Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for first quarter 2012 following the close of market on Monday, April 23, 2012.

On the same day, at 2:00pm Pacific Time (5:00pm Eastern Time) Jay Flatley, President and Chief Executive Officer; Christian Henry, Senior Vice President and General Manager, Genomic Solutions; and Marc Stapley, Senior Vice President and Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Conference Call Details

The conference call will begin at 2:00pm Pacific Time (5:00pm Eastern Time) on Monday, April 23, 2012. Interested parties may listen to the call by dialing 888.679.8038 (passcode: 40633465), or if outside North America, by dialing +1.617.213.4850 (passcode: 40633465). Individuals may access the live teleconference in the Investor Relations section of Illumina's web site under the "Company" tab at www.illumina.com.

A replay of the conference call will be available from 4:00pm Pacific Time (7:00pm Eastern Time) on April 23, 2012 through April 30, 2012 by dialing 888.286.8010 (passcode: 55576523), or if outside North America, by dialing +1.617.801.6888 (passcode: 55576523).

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

SOURCE: Illumina, Inc.

Illumina, Inc.
Investors:
Kevin Williams, MD
Investor Relations
858-332-4989
kwilliams@illumina.com
or
Media:
Jennifer Temple
Public Relations
858-429-8350
pr@illumina.com

Recent Articles

Giving students a new window on genomic technologies
Giving students a new window on genomic technologies
Nucleus Genomics wants to make personalized health care a reality
Nucleus Genomics wants to make personalized health care a reality
DRAGEN takes the mystery out of cardiovascular disease
DRAGEN takes the mystery out of cardiovascular disease